Progress in Neuro-Psychopharmacology and Biological Psychiatry
April 2, 2025
Simon Reiche, Tim Hirschfeld, Anna Lena Gröticke et al.
5 citations
Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known about how sporadic use of psychedelics under naturalistic conditions may affect cognitive functioning. Given the growing interest in the therapeutic potential of psychedelics and the rise in non-medical use, further exploration into their...
International Journal of Mental Health and Addiction
April 1, 2025
Joshua C. Black, Nicole Schow, Hannah L. Burkett et al.
3 citations
Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...
Molecular Psychiatry
April 1, 2025
Devon Stoliker, Katrin H. Preller, Leonardo Novelli et al.
19 citations
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agonism of the 5-HT2A receptor may reduce synaptic gain to produce psychedelic-induced imagery. However, this has not been investigated in humans. To infer the directed connectivity changes to visual connectivity underlying psychedelic visual imagery in...
Cureus
April 1, 2025
Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq
1 citation
This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...
Psychological Medicine
March 31, 2025
Otto Simonsson, Simon B. Goldberg, Walter Osika et al.
16 citations
BACKGROUND: Findings from contemporary clinical trials suggest that psychedelics are generally safe and may be effective in the treatment of various psychiatric disorders. However, less is known about the risks associated with psychedelic use outside of medically supervised contexts, particularly in populations that are typically excluded from participation in clinical trials. METHODS:...
Journal of Psychoactive Drugs
March 31, 2025
Samuel Thomson, Nikos Thomacos
11 citations
Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4,...
Journal of Psychopharmacology
March 31, 2025
Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke et al.
4 citations
Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic afterglow,” a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute...
Psychopharmacology
March 26, 2025
Laura Ley, Matthias E. Liechti, Anna M Becker et al.
3 citations
Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively. This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience...
Journal of Humanistic Psychology
March 22, 2025
M. Cirillo
There are substantial differences between the current FDA and research-driven approach to psychedelic use in Western cultures and traditional uses among Indigenous peoples. While the research-driven, evidence-based approach to identifying risks and benefits for particular conditions used in the United States and elsewhere helps ensure safety and efficacy, there is a risk of failing to...
Advanced Science
March 20, 2025
Sung‐hyun Kim, Sumin Yang, Jeehye Jung et al.
5 citations
Abstract Mental disorders are a representative type of brain disorder, including anxiety, major depressive depression (MDD), and autism spectrum disorder (ASD), that are caused by multiple etiologies, including genetic heterogeneity, epigenetic dysregulation, and aberrant morphological and biochemical conditions. Psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have...